Back to top
more

Masimo (MASI)

(Delayed Data from NSDQ)

$143.49 USD

143.49
736,466

+3.55 (2.54%)

Updated Oct 9, 2024 04:00 PM ET

After-Market: $143.53 +0.04 (0.03%) 6:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (94 out of 252)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Cerner's CommunityWorks Picked by Reeves County Hospital

Cerner (CERN) sees a slew of developments in its EHR platform, market prospects bright.

    Cardiovascular Systems Stealth 360 Peripheral OAS Goes Global

    Following the recent extension of its partnership with OrbusNeich, Cardiovascular Systems' (CSII) Stealth 360 Peripheral OAS is put to first commercial use in Hong Kong.

      Insulet Advances on Omnipod Reimbursement Update, Runs Risks

      Insulet (PODD) commences 2018 with favorable reimbursement updates. The company attains several landmarks regarding Omnipod's market reach.

        Here's Why You Should Hold on to Align Technology (ALGN) Now

        Continued strength in Align Technology's (ALGN) Invisalign volumes impresses. Overdependence on Invisalign Technology system is a concern.

          Here's Why You Should Invest in Masimo (MASI) Right Now

          A raised guidance for 2018 and positive developments make Masimo (MASI) a lucrative choice for investors.

            ResMed Unveils AirFit F30, Expands AirFit Mask Portfolio

            ResMed's (RMD) recent product launches will strengthen its position in the high-potential sleep-disordered breathing market.

              QIAGEN (QGEN) Partners DiaSorin to Extend QuantFERON Offers

              Per QIAGEN (QGEN), the latest LIAISON QuantiFERON-TB Plus Test is likely to tackle the growing transformation of global latent TB testing market into the modern blood-based QuantiFERON technology.

                Cooper's MiSight Lens Effective in Checking Juvenile Myopia

                Cooper's (COO) core CVI business gets a boost from MiSight's positive study results.

                  Here's Why You Should Add Abbott (ABT) to Your Portfolio Now

                  Abbott (ABT) continues to deliver strong and consistent performance in all segments. The company has also been hogging the limelight within Diabetic Care on progress with its FreeStyle Libre.

                    CVS Health (CVS) PBM Strengthens, Aetna Deal Shows Promise

                    A robust 2019 PBM selling season is a tailwind for CVS Health (CVS). Additionally, the company's milestone acquisition of Aetna might alter the whole healthcare landscape in the United States.

                      QIAGEN Collaborates With NeuMoDx, Expands NGS Portfolio

                      QIAGEN (QGEN) forges ahead with deals to strengthen the NGS Platform.

                        DaVita Kidney Care Opens 150000-Square-Foot Campus in DeLand

                        DaVita's (DVA) dialysis care in the United States gets a boost; market prospects solid.

                          Omnicell Continues to Pursue Buyouts, Costs on the Rise

                          Omnicell (OMCL) progresses well with its strategy to grow inorganically. Rising operating expenses a concern.

                            AngioDynamics (ANGO) to Acquire RadiaDyne, Boost Oncology

                            AngioDynamics' (ANGO) agreement to acquire RadiaDyne is expected to close by the end of September. The RadiaDyne acquisition will expand the Oncology segment.

                              Cardiovascular Systems Portfolio Strong, Competition Rife

                              Cardiovascular Systems (CSII) suffers a long history of net loss since its launch in 1989 with no immediate solution in sight.

                                Pacific Biosciences (PACB) Up as VGP Picks Flagship Sequel

                                Pacific Biosciences (PACB) sees a slew of developments in its coveted SMRT Sequel platform.

                                  DENTSPLY Launches Azento, Improves Digital Implant Workflow

                                  DENTSPLY's (XRAY) Azento is a unique dental platform that will help dentists select the best-fitting implant, optimal implant positioning and feasible healing environment.

                                    Here's Why You Should Invest in Penumbra (PEN) Stock Now

                                    The market is quite upbeat about Penumbra's (PEN) recently-closed buyout of a controlling stake in MVI Health, aimed at capturing the great potential of virtual reality application.

                                      Here's Why You Should Retain IDEXX (IDXX) in Your Portfolio

                                      IDEXX (IDXX) continues to see strong organic growth. Adverse currency movement is a concern.

                                        Nabaparna Bhattacharya headshot

                                        Allscripts' Sunrise Abstracting Selected by Wyckoff Heights

                                        Allscripts' (MDRX) Sunrise Abstracting Solution gets picked by Wyckoff Heights Medical Center. The platform complements Allscripts Sunrise electronic health record unit.

                                          Medtronic (MDT) Initiates ONYX ONE- Clear Study on DAPT

                                          Following a DAPT interruption at one month on patients with a next generation DES, the Onyx ONE Clear Study by Medtronic (MDT) investigates risk of cardiac death, heart attack and stent thrombosis.

                                            Here's Why You Should Retain QIAGEN (QGEN) in Your Portfolio

                                            A tough competitive landscape and strong reliance on relationships with collaborative partners is a major deterrent to QIAGEN (QGEN). The company's increased focus on the NGS portfolio is a positive.

                                              Stryker (SYK) to Acquire Invuity, Boost Surgical Portfolio

                                              Stryker (SYK) on an acquisition spree; latest buyout likely to aid its array of surgical instruments.

                                                Genomic Health (GHDX) Hits a 52-Week High: What's Driving It?

                                                Genomic Health (GHDX) sees increasing private coverage for the Oncotype DX GPS test within the prostate cancer space.

                                                  Here's Why You Should Hold On to DaVita (DVA) Stock Now

                                                  Strong prospects in the Kidney Care segment to drive DaVita (DVA) stock over the long haul.